DLBCL is the most common lymphoma subtype among non-Hodgkin's lymphomas in adults and DLBCLs constitute 30-58% of non-Hodgkin's lymphomas. It characteristically presents an advanced stage, both in nodal and in extranodal symptomatic disease, with a median age of 60, representing an important disease holding a practical objective of treatment represented by a curative approach. The disease usually presents as a nodal or extranodal mass and systemic symptoms. DLBCL symptoms; fever, night sweats and unexplained weight loss. These are known as ‘B symptoms’. Fatigue and loss of appetite are also quite common.
Excisional lymph node biopsy should be preferred for diagnosis. For more information, please visit
Treatment of diffuse large B-cell lymphoma varies according to the patient's age, stage of the disease and the location of involvement in the body. In early stage DLBCL, radiation therapy is used to stop or slow down organ involvement. If the disease is advanced, chemotherapy and immunotherapy methods can be used together.
References
“Leticia Quintanilla‐Martinez. The 2016 updated WHO classification of lymphoid neoplasms. Hematological Oncology. 2017;35(S1):37–45.” http://www.kimia-pharma.co/UserFile/Download/hon.2399.pdf [Accessed: July 2023]
H. Tilly, M. Gomes da Silva et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 26 (Supplement 5): v116–v125, 2015. https://www.annalsofoncology.org/ [Accessed: July 2023]